Bimekizumab (Bimzelx) has been EMA approved to treat adults with active PsA & axial spondylarthritis in the EU. This
Tweet Content
Bimekizumab (Bimzelx) has been EMA approved to treat adults with active PsA & axial spondylarthritis in the EU. This dual IL-17 A/F inhibitor is approved to treat moderate -severe plaque psoriasis in the EU, Canada, UK & Japan; but not yet in USA https://t.co/kmjo3HYg4K https://t.co/PINZryXQBP
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off